Adverum Biotechnologies, Inc.
ADVM
$2.91
-$0.06-2.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.22% | 21.50% | 21.45% | 19.11% | 20.98% |
| Total Depreciation and Amortization | -35.28% | -39.31% | -32.52% | -24.59% | -13.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.52% | -27.46% | 22.59% | 48.28% | 41.59% |
| Change in Net Operating Assets | 110.71% | -674.40% | -314.57% | -182.31% | -153.68% |
| Cash from Operations | -1.72% | 2.85% | 7.94% | 9.69% | 15.90% |
| Capital Expenditure | 51.98% | 35.21% | 29.82% | 89.20% | 93.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -142.49% | -142.86% | -113.11% | -37.35% | -36.38% |
| Cash from Investing | -143.24% | -143.65% | -113.92% | -32.40% | -31.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 24,464.21% | 24,464.83% | 24,515.37% | 19,828.64% | -19.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 77.91% | 23.53% | -- | -- |
| Cash from Financing | 173,817.39% | 82,610.34% | 47,830.00% | 19,759.11% | -88.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -337.47% | -162.56% | -20.57% | 468.91% | -82.35% |